Bellerophon Therapeutics (NASDAQ:BLPH) received FDA orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF) with nitric oxide. IPF is a progressive and fatal lung disease caused by the...
Verrica Pharmaceuticals (NASDAQ:VRCA) submitted an NDA to the FDA for its molluscum contagiosum drug candidate, VP-102. Molluscum contagiosum is a viral skin infection that currently has no FDA-approved therapies. VP...
Wave Life Sciences (NASDAQ:WVE) received FDA fast track designation for suvodirsen for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disorder caused by the absence of dystrophin – a protein that...
TG Therapeutics (NASDAQ:TGTX) presented initial Phase 3 and updated Phase 2 data for ublituximab, an anti-CD20 monoclonal antibody, for the treatment of relapsing forms of multiple sclerosis (RMS). At the 35th Annual...
Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP). BP is a severe orphan inflammatory skin disease characterized by chronic blistering of...
Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) is opening a new PoNS clinic in Quebec City, Canada to be operated by Clinique Cortex. The PoNS device is authorized in Canada for the acute treatment of chronic...
The U.S. Patent and Trademark Office (USPTO) gave INmune Bio (NASDAQ: INMB) notice of allowance for a patent, which covers the company’s INB03 program utilizing its dominant negative tumor necrosis factor–alpha (DN-TNF...
BeyondSpring (NASDAQ: BYSI) presented a poster of the design for its Phase 3 Study 103 at the International Association for the Study of Lung Cancer (IASLC) in Barcelona, Spain on Sept. 9. Study 103 is a multi-center...
Zenabis Global (TSX:ZENA) inked a supply agreement with the Ontario Cannabis Retail Corp. (OCS) to supply adult-use recreational cannabis to retailers throughout the province. Zenabis will begin supplying OCS with 21...
Toronto Innovation Acceleration Partners (TIAP), formerly MaRS Innovation, and Amgen (NASDAQ:AMGN) are collaborating to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member...
Soricimed Biopharma entered into a strategic alliance with Image Analysis Group for the development of Soricimed’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. Image...
The New England Journal of Medicine published results from a landmark clinical trial called, “Patient Outcome after Primary PCI” (POPular Genetics), that included genetic testing using the Spartan RX CYP2C19 rapid...
Precipio (NASDAQ:PRPO) inked a new joint collaboration with the Department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania to expand cancer patient access to...
Versant Ventures launched an independent new venture capital and growth equity investment firm dedicated to the medtech sector. Vensana Capital debuted with the closing of its inaugural fund, Vensana Capital I, with...
Aerie Pharmaceuticals (NASDAQ:AERI) priced $275-million principal amount of 1.5% convertible senior notes due 2024. The offering was increased to $275-million from a previously announced size of $250-million. The notes...
Closely-held Repare Therapeutics completed an $82.5-million Series B financing as it prepares to take its lead synthetic lethality therapy into human testing in 2020. Cowen Healthcare Investments led the financing and...
The results of Paratek Pharmaceuticals’ (NASDAQ:PRTK) Phase 3 trial of NUZYRA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) have been published in the peer-reviewed journal, The Lancet...
Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients. HSCT...
Zenabis Global’s (TSX:ZENA) cultivation output in July 2019 was 1,238 kg of dried cannabis, which represents a 46.2% outperformance relative to original design capacity and a 12.9% outperformance relative to revised...
Zenabis Global (TSX:ZENA) has secured a supply of cannabis-infused inputs for the production of cannabis-infused beverages and other products. Under the accord, Zenabis will provide cannabis to anunnamed beverage...
Closely-held Satsuma Pharmaceuticals dosed the first patient in its Phase 3 efficacy trial of STS101 for the acute treatment of migraine. STS101 is a drug-device combination of dihydroergotamine mesylate (DHE) dry...